Myriad Genetics (MYGN +3%) finished the day solidly higher on the back of a New York Times op-ed piece by Angelina Jolie outlining her decision to have a double mastectomy after learning she had an 87% chance of developing breast cancer. MYGN holds the patent on the test that made the determination, as well as the genes themselves. The test looks for defects in the BRCA1 or BRCA2 genes, which are the cause of most hereditary breast cancer cases.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Mon, 8:47AM)
at Benzinga.com (Wed, 3:34PM)
at Nasdaq.com (Feb 12, 2015)
at Nasdaq.com (Jan 29, 2015)
at Nasdaq.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs